Skip to main content
. 2022 Dec 14;118(5):861–871. doi: 10.14309/ajg.0000000000002129

Figure 2.

Figure 2.

Loss of response over time to tofacitinib, overall (a) and by: (b) baseline Mayo endoscopic subscore (MES; log-rank P value = 0.004), (c) maintenance dosing (P = 0.008), and (d) biologic exposure (P = 0.07). BID, twice daily.